P
Pfizer
Pfizer settled a $35 million class action alleging it unlawfully delayed generic Lipitor versions from entering the market.
ClosedSelected statesClaim status: Closed on November 29, 2024Payout: VariesNo longer claimable
About this settlement
The case addresses alleged antitrust violations by Pfizer related to Lipitor and generic atorvastatin calcium purchases.
This settlement resolves claims that Pfizer unlawfully delayed generic versions of Lipitor, a cholesterol-lowering medication, from entering the market, affecting consumers and third-party payors in multiple states.
Who qualifies
- Individuals who purchased or reimbursed branded Lipitor or generic atorvastatin calcium in specified states during the relevant periods.
- Third-party payors who purchased or reimbursed these medications in the same states and periods.
Varies
Claim status: Closed on November 29, 2024